Konstantin Zakashansky, MD

Konstantin Zakashansky, MD, discusses data with olaparib in advanced, recurrent, platinum-sensitive, BRCA-mutated ovarian cancer.

Konstantin Zakashansky, MD, discusses repeat exposure to PARP inhibition in patients with platinum-sensitive, relapsed ovarian cancer.

Konstantin Zakashansky, MD, gynecologic oncologist and associate professor of Obstetrics, Gynecology and Reproductive Science at Mount Sinai Health System, discusses repeat exposure to PARP inhibition in patients with platinum-sensitive, relapsed ovarian cancer.

Konstantin Zakashansky, MD, discusses final overall survival data from the phase 3 SOLO2 trial evaluating maintenance olaparib (Lynparza) in platinum-sensitive, relapsed ovarian cancer with a BRCA mutation.